Amarin Corporation Appoints Paul E. Huff as Chief Commercial Officer
Amarin Corporation plc announced that Paul E. Huff has joined the Company as Chief Commercial Officer. In this role, Mr. Huff is responsible for driving Amarin’s AMR101 commercialization strategy, including all marketing and sales planning and implementation, including product launch activities. He will also provide business development support as Amarin evaluates potential strategic partnerships for the commercialization of AMR101.
Mr. Huff brings more than 25 years of cardiovascular-focused pharmaceutical marketing and sales experience to Amarin, with a special emphasis on marketing lipid-modifying prescription pharmaceuticals. He has held senior-level sales and marketing positions with a number of pharmaceutical and biotechnology companies, including Reliant Pharmaceuticals, where as Vice President of Marketing, he played a pivotal role in the launch and successful commercialization of Lovaza, the leading prescription Omega-3 product for reducing triglycerides, and later was a contributor to activities leading to the sale of Reliant Pharmaceuticals for $1.65 billion. Similarly, at Kos Pharmaceuticals he played an integral role in the launch and successful commercialization of Niaspan, the leading prescription drug for raising HDL cholesterol. Mr. Huff received a B.S. in marketing from the University of Maryland.
In addition, the Company announced that it intends to create a U.S. sales and marketing headquarters in New Jersey. The Company’s U.S. R&D headquarters will remain in Connecticut.
Other news from the department people
